GLP-1 Drugs Linked To Lower Risks Of Addiction, Overdose And Drug-Related Death
Widely used GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound may do far more than control blood sugar and body weight. New research suggests they are also associated with significantly lower risks of addiction, overdose and drug-related death across a range of substances.
In one of the largest analyses to date, researchers from Washington University School of Medicine and the U.S. Department of Veterans Affairs found that GLP-1 users had lower odds of developing new substance use disorders. Among those already diagnosed with addiction, they also experienced fewer overdoses, hospitalizations and fatalities.
Large Study Of U.S. Veterans
The team analyzed electronic health records from 606,434 U.S. veterans with type 2 diabetes. Participants began treatment with either a GLP-1 receptor agonist, such as semaglutide, liraglutide or dulaglutide, or an alternative diabetes medication known as an SGLT2 inhibitor.
Of these patients, 524,817 had no history of substance use disorder when the study began, while 81,617 already had a diagnosed addiction. Researchers followed outcomes for up to three years, tracking new diagnoses, emergency department visits, hospitalizations, overdoses and drug-related deaths.
To reduce bias, the study compared patients with similar health characteristics who differed primarily in whether they were prescribed a GLP-1 drug or an SGLT2 inhibitor. The findings, published in The BMJ, add support to earlier, smaller studies that hinted at a potential anti-addiction effect.
Lower Risk Of Developing Addiction
Among veterans without an existing substance use disorder, GLP-1 drugs were associated with a 14% lower risk of developing any new addiction compared with the alternative medications. The protective association appeared across every major substance category examined.
Patients receiving GLP-1 therapy showed lower risks of alcohol use disorder, cannabis use disorder, cocaine use disorder, nicotine dependence and opioid use disorder. Estimated reductions ranged from approximately 14% to 25%, depending on the substance.
In practical terms, the researchers estimated that GLP-1 treatment was associated with about seven fewer new substance use disorder diagnoses per 1,000 patients over three years. While modest at the individual level, these effects could translate into substantial public health benefits when applied to millions of users.
Fewer Overdoses And Deaths
Among participants already living with addiction, the potential benefits appeared even more pronounced. GLP-1 use was associated with a 30% reduction in substance use-related emergency department visits and a 25% reduction in related hospital admissions.
The risk of overdose was approximately 40% lower among veterans receiving GLP-1 therapy compared with those taking other diabetes medications. Drug-related mortality was reduced by roughly 50%, according to the study’s estimates over three years of follow-up.
Overall, the researchers estimated that GLP-1 use was associated with 12 fewer serious addiction-related events per 1,000 patients, including overdoses and deaths. Given the continuing impact of the U.S. overdose crisis, even relatively small reductions could have meaningful clinical significance.
Targeting Cravings In The Brain
The study was partly inspired by reports from patients who said they lost interest in alcohol or cigarettes after starting GLP-1 treatment. These observations align with growing evidence that GLP-1 receptors are present in brain regions involved in reward, motivation and craving.
Senior author Ziyad Al-Aly said the findings support the idea that these medications may act on a shared biological pathway underlying multiple forms of addiction. Rather than targeting a specific substance, they may reduce the cravings that drive compulsive use.
Al-Aly compared the effect to the reduction in “food noise” commonly reported by people taking GLP-1 medications for obesity. He suggests that a similar reduction in “drug noise” may help individuals resist urges to drink alcohol, smoke or use illicit substances.
Promise And Unanswered Questions
There are currently few medications that work across multiple types of substance use disorders, and some addictions, including methamphetamine use disorder, have no approved drug treatment. If confirmed in randomized clinical trials, GLP-1 therapies could represent a rare broad-spectrum option.
However, the researchers emphasize that their study was observational and cannot establish cause and effect. Factors such as differences in healthcare access, treatment patterns or underlying health conditions may partially explain the associations observed in veterans.
Experts also note that GLP-1 drugs carry potential side effects, including nausea, gastrointestinal symptoms and rare but serious complications. They are also costly and have periodically faced supply shortages, raising concerns about access and appropriate prescribing.
Next Steps For Research And Policy
The authors argue that the findings should encourage dedicated clinical trials evaluating GLP-1 therapies as primary treatments for addiction. Such studies would need to assess not only cravings and substance use but also major outcomes such as overdose and mortality.
Millions of people already use GLP-1 drugs for diabetes or obesity, and that number continues to grow. If future trials confirm the benefits suggested by this analysis, clinicians may eventually use a single class of medication to address both metabolic disease and substance use disorders.
The research was funded by the U.S. Department of Veterans Affairs, although the authors state that the agency had no role in the study’s design, analysis or publication. They also emphasize that the findings reflect the views of the researchers, not official U.S. government policy, highlighting the need for further independent investigation.
